Pedram Razavi

List of Publications by Year
in descending order

52 papers	9,991 citations	186265 28 h-index	175258 52 g-index
56 all docs	56 docs citations	56 times ranked	16734 citing authors

#	ARTICLE	IF	CITATIONS
1	INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. Cancer Discovery, 2022, 12, 356-371.	9.4	68
2	The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features. Modern Pathology, 2022, 35, 193-201.	5.5	25
3	Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome. Clinical Cancer Research, 2022, 28, 404-413.	7.0	13
4	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	28.9	223
5	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. Npj Breast Cancer, 2022, 8, 37.	5.2	9
6	Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nature Medicine, 2022, 28, 946-957.	30.7	50
7	The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer. Clinical Cancer Research, 2022, 28, 3603-3617.	7.0	7
8	10-Year Breast Cancer Outcomes in Women ≥85 Years of Age. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1007-1018.	0.8	14
9	Next-generation assessment of human epidermal growth factor receptor 2 gene (*ERBB2*) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline. Histopathology, 2021, 78, 498-507.	2.9	7
10	Accuracy of Magnetic Resonance Imaging–Guided Biopsy to Verify Breast Cancer Pathologic Complete Response After Neoadjuvant Chemotherapy. JAMA Network Open, 2021, 4, e2034045.	5.9	19
11	Genomic Alterations in *PIK3CA*-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors. Cancer Research, 2021, 81, 2470-2480.	0.9	20
12	Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. Npj Breast Cancer, 2021, 7, 44.	5.2	11
13	TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. Npj Breast Cancer, 2021, 7, 43.	5.2	16
14	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Medicine, 2021, 13, 96.	8.2	26
15	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nature Communications, 2021, 12, 3770.	12.8	68
16	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. Lung Cancer, 2021, 159, 66-73.	2.0	17
17	AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling. Molecular Cancer Research, 2021, 19, 573-584.	3.4	10
18	HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nature Communications, 2021, 12, 6667.	12.8	47

#	Article	IF	Citations
19	Liquid biopsies for residual disease and recurrence. Med, 2021, 2, 1292-1313.	4.4	15
20	Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. JAMA Oncology, 2020, 6, 84.	7.1	66
21	Metabolic Imaging Detects Resistance to PI3KÎ± Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer. Cancer Cell, 2020, 38, 516-533.e9.	16.8	38
22	The genomic landscape of metastatic histologic special types of invasive breast cancer. Npj Breast Cancer, 2020, 6, 53.	5.2	27
23	Regional Lymph Node Involvement Among Patients With De Novo Metastatic Breast Cancer. JAMA Network Open, 2020, 3, e2018790.	5.9	10
24	FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. Cancer Cell, 2020, 38, 534-550.e9.	16.8	67
25	Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. Genome Medicine, 2020, 12, 78.	8.2	10
26	A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy. Breast Cancer Research, 2020, 22, 57.	5.0	63
27	ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nature Genetics, 2020, 52, 198-207.	21.4	140
28	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nature Cancer, 2020, 1, 382-393.	13.2	96
29	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. Clinical Cancer Research, 2020, 26, 3720-3731.	7.0	21
30	HER2-Mediated Internalization of Cytotoxic Agents in<i>ERBB2</i>Amplified or Mutant Lung Cancers. Cancer Discovery, 2020, 10, 674-687.	9.4	149
31	Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature Medicine, 2019, 25, 1422-1427.	30.7	144
32	Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3KÎ± inhibitors. Science, 2019, 366, 714-723.	12.6	185
33	Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers. Nature Communications, 2019, 10, 4369.	12.8	18
34	Shift Work, Chronotype, and Melatonin Rhythm in Nurses. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1177-1186.	2.5	96
35	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nature Medicine, 2019, 25, 1928-1937.	30.7	485
36	Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. Modern Pathology, 2019, 32, 81-87.	5.5	10

#	ARTICLE	IF	CITATIONS
37	Next-Generation Sequencingâ€"Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer. Journal of Molecular Diagnostics, 2019, 21, 307-317.	2.8	19
38	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	21.4	2,702
39	Molecular profiling of ER+ metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors.. Journal of Clinical Oncology, 2019, 37, 1009-1009.	1.6	13
40	Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer Discovery, 2018, 8, 174-183.	9.4	275
41	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell, 2018, 34, 893-905.e8.	16.8	307
42	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science Signaling, 2018, 11, .	3.6	53
43	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 2018, 34, 427-438.e6.	16.8	633
44	KMT2C mediates the estrogen dependence of breast cancer through regulation of ERÎ± enhancer function. Oncogene, 2018, 37, 4692-4710.	5.9	102
45	Genome doubling shapes the evolution and prognosis of advanced cancers. Nature Genetics, 2018, 50, 1189-1195.	21.4	411
46	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	30.7	2,473
47	A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Investigational New Drugs, 2017, 35, 742-750.	2.6	10
48	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status. Journal of Molecular Diagnostics, 2017, 19, 244-254.	2.8	96
49	Activating <i>ESR1</i> Mutations Differentially Affect the Efficacy of ER Antagonists. Cancer Discovery, 2017, 7, 277-287.	9.4	286
50	Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA. Journal of Oncology, 2017, 2017, 1-5.	1.3	20
51	Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. Cancer Discovery, 2016, 6, 1134-1147.	9.4	106
52	PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3KÎ± Inhibition. Cancer Cell, 2016, 30, 229-242.	16.8	187